Mengyang Li1, Jinfeng Qu1, Zhiqiao Liang1, Jiyang Tang1, Jie Hu1, Yuou Yao1, Enzhong Jin1, Xiaoxin Li1, Mingwei Zhao2. 1. Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 S Ave of XiZhiMen, XiCheng District, Beijing, 100044, People's Republic of China. 2. Department of Ophthalmology, Peking University People's Hospital, Eye Diseases and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 S Ave of XiZhiMen, XiCheng District, Beijing, 100044, People's Republic of China. zhaomingwei64@163.com.
Abstract
PURPOSE: To investigate the prognostic factors on spectral domain optical coherence tomography (SD-OCT) associated with incomplete subretinal fluid (SRF) absorption in treated-naïve eyes with central serous chorioretinopathy (CSC) after the half-dose verteporfin photodynamic therapy (vPDT). METHODS: Patients with CSC who underwent half-dose vPDT with a follow-up period of more than 3 months were included in this retrospective study. Logistic regression was performed to determine the risk factors associated with the SRF persistence at 3 months after the treatment. RESULTS: A total of 143 patients with 150 eyes were enrolled in this study (102 male and 41 female patients). The rate of complete SRF resolution was 82.7% at 3 months for all cases. The duration of symptoms > 6 months (odds ratio [OR] = 3.135, 95% confidence interval [95% CI] (1.147-8.573), p = 0.026), larger SRF area with base diameter > 3 mm (odds ratio (OR) = 4.051, 95% CI: 1.336-12.284, p = 0.013), and larger flat irregular pigment epithelium detachment (FI-PED) area with base diameter > 1 mm (OR = 3.311, 95% CI: 1.249-8.780, p = 0.016) on OCT B-scans were risk factors for incomplete SRF absorption after half-dose vPDT, while outer nuclear layer (ONL) thickness was not significantly associated with the anatomical outcome (OR = 1.015, 95% CI: 0.995-1.036, p = 0.145). CONCLUSION: The duration of symptoms, baseline SRF, and FI-PED base diameter on SD-OCT were important predictors for the anatomical outcome at 3 months after half-dose vPDT. Further studies are needed to establish a better therapeutic strategy for patients with poor response to half-dose vPDT.
PURPOSE: To investigate the prognostic factors on spectral domain optical coherence tomography (SD-OCT) associated with incomplete subretinal fluid (SRF) absorption in treated-naïve eyes with central serous chorioretinopathy (CSC) after the half-dose verteporfin photodynamic therapy (vPDT). METHODS: Patients with CSC who underwent half-dose vPDT with a follow-up period of more than 3 months were included in this retrospective study. Logistic regression was performed to determine the risk factors associated with the SRF persistence at 3 months after the treatment. RESULTS: A total of 143 patients with 150 eyes were enrolled in this study (102 male and 41 female patients). The rate of complete SRF resolution was 82.7% at 3 months for all cases. The duration of symptoms > 6 months (odds ratio [OR] = 3.135, 95% confidence interval [95% CI] (1.147-8.573), p = 0.026), larger SRF area with base diameter > 3 mm (odds ratio (OR) = 4.051, 95% CI: 1.336-12.284, p = 0.013), and larger flat irregular pigment epithelium detachment (FI-PED) area with base diameter > 1 mm (OR = 3.311, 95% CI: 1.249-8.780, p = 0.016) on OCT B-scans were risk factors for incomplete SRF absorption after half-dose vPDT, while outer nuclear layer (ONL) thickness was not significantly associated with the anatomical outcome (OR = 1.015, 95% CI: 0.995-1.036, p = 0.145). CONCLUSION: The duration of symptoms, baseline SRF, and FI-PED base diameter on SD-OCT were important predictors for the anatomical outcome at 3 months after half-dose vPDT. Further studies are needed to establish a better therapeutic strategy for patients with poor response to half-dose vPDT.
Authors: C Nathaniel Roybal; Elisabeth Sledz; Yasser Elshatory; Li Zhang; David R P Almeida; Eric K Chin; Brice Critser; Michael D Abramoff; Stephen R Russell Journal: Retina Date: 2018-06 Impact factor: 4.256
Authors: Thomas J van Rijssen; Elon H C van Dijk; Suzanne Yzer; Kyoko Ohno-Matsui; Jan E E Keunen; Reinier O Schlingemann; Sobha Sivaprasad; Giuseppe Querques; Susan M Downes; Sascha Fauser; Carel B Hoyng; Felice Cardillo Piccolino; Jay K Chhablani; Timothy Y Y Lai; Andrew J Lotery; Michael Larsen; Frank G Holz; K Bailey Freund; Lawrence A Yannuzzi; Camiel J F Boon Journal: Prog Retin Eye Res Date: 2019-07-15 Impact factor: 21.198
Authors: Christopher K Hwang; Elvira Agrón; Amitha Domalpally; Catherine A Cukras; Wai T Wong; Emily Y Chew; Tiarnan D L Keenan Journal: Ophthalmol Retina Date: 2020-10-16